综合性医院门诊幽门螺杆菌感染及耐药情况研究

doi:10.20223/j.cnki.1000-8535.2025.12.008

广州医药 ›› 2025, Vol. 56 ›› Issue (12): 1669-1676.DOI: 10.20223/j.cnki.1000-8535.2025.12.008

综合性医院门诊幽门螺杆菌感染及耐药情况研究

文学^1,2, 魏珊珊², 刘伟², 熊慧珍², 钟剑锋², 陈泓磊², 柳芳²

1 中山大学（广东广州 510275）
2 中山大学附属第八医院消化内镜中心（广东深圳 518033）

收稿日期:2025-02-17 出版日期:2025-12-20 发布日期:2026-01-20
通讯作者: 柳芳,E-mail：liuf279@mail.sysu.edu.cn
基金资助:
深圳市福田区卫生健康系统科研项目（FTWS2023001、FTWS2023028）; 中大八院培育计划资助项目（PY-2023-03）

Investigation of Helicobacter pylori infection and antibiotic resistance in outpatients at a general hospital

WEN Xue^1,2, WEI Shanshan², LIU Wei², XIONG Huizhen², ZHONG Jianfeng², CHEN Honglei², LIU Fang²

1 Sun Yat-sen University,Guangzhou 510275,China
2 Department of Digestive Endoscopy,the Eighth Affiliated Hospital,Sun Yat-sen University,Shenzhen 518033,China

Received:2025-02-17 Online:2025-12-20 Published:2026-01-20

摘要/Abstract

摘要： 目的调查深圳地区综合性医院门诊幽门螺杆菌（Hp）对8种常见抗菌药物的耐药情况。方法采集¹³C呼气试验阳性的患者胃黏膜标本313例,进行Hp分离培养及抗菌药物敏感性试验。结果 313例患者分离培养得到247例Hp菌株,培养阳性率78.91%,不同性别、不同年龄患者Hp分离培养阳性率比较差异无统计学意义（P>0.05）。Hp对甲硝唑、克拉霉素、左氧氟沙星、利福平、阿莫西林、四环素、呋喃唑酮、庆大霉素耐药率依次为88.66%（219/247）、38.46%（95/247）、38.06%（94/247）、4.05%（10/247）、1.21%（3/247）、0.40%（1/247）、0.40%（1/247）、0（0/247）。双重耐药率为38.46%（95/247）,其中Hp对克拉霉素+甲硝唑组合耐药率最高（18.62%,46/247）,对甲硝唑+左氧氟沙星耐药率居其次（17.00%,42/247）。多重耐药率为19.84%（49/247）。不同年龄、性别患者双重耐药率、多重耐药率比较差异均无统计学意义（P>0.05）。结论深圳地区分离的Hp菌株对甲硝唑、克拉霉素、左氧氟沙星耐药率相对更高,且双重耐药、多重耐药情况严重。

关键词: 幽门螺杆菌, 分离培养, 纸片扩散法, 抗菌药物耐药性

Abstract: Objective To investigate the antibiotic resistance of Helicobacter pylori（Hp）to eight commonly used antibiotics in outpatients of general hospitals in Shenzhen．Methods Gastric mucosal samples were collected from 313 patients who tested positive for the ¹³C breath test,and Hp strains were isolated and cultured．Antibiotic susceptibility testing was performed on the isolated Hp strains．Results Of the 313 patients,247 Hp strains were isolated,with a culture-positive rate of 78.91%．There was no significant difference in culture-positive rates between different genders and age groups（P>0.05）．The resistance rates to metronidazole,clarithromycin,levofloxacin,rifampicin,amoxicillin,tetracycline,furazolidone,and gentamicin were 88.66%（219/247）,38.46%（95/247）,38.06%（94/247）,4.05%（10/247）,1.21%（3/247）,0.40%（1/247）,0.40%（1/247）,0（0/247）,respectively．The dual resistance rate was 38.46%（95/247）,with the highest combination resistance observed in clarithromycin + metronidazole（18.62%,46/247）,followed by metronidazole + levofloxacin（17.00%,42/247）．The multi-drug resistance rate was 19.84%（49/247）．There were no significant differences in dual resistance rates（P>0.05）or multiple resistance rates（P>0.05）between different age groups and genders．Conclusions The Hp strains isolated in Shenzhen exhibited relatively higher resistance rates to metronidazole,clarithromycin,and levofloxacin,with substantial dual and multi-drug resistance．

Key words: Helicobacter pylori, isolation and culture, disk diffusion method, antibiotic resistance

文学, 魏珊珊, 刘伟, 熊慧珍, 钟剑锋, 陈泓磊, 柳芳. 综合性医院门诊幽门螺杆菌感染及耐药情况研究[J]. 广州医药, 2025, 56(12): 1669-1676.

WEN Xue, WEI Shanshan, LIU Wei, XIONG Huizhen, ZHONG Jianfeng, CHEN Honglei, LIU Fang. Investigation of Helicobacter pylori infection and antibiotic resistance in outpatients at a general hospital[J]. Guangzhou Medical Journal, 2025, 56(12): 1669-1676.

参考文献

[1] ZAMANI M,EBRAHIMTABAR F,ZAMANI V,et al.Systematic review with meta-analysis:The worldwide prevalence of Helicobacter pylori infection[J].Aliment Pharmacol Ther,2018,47(7):868-876.
[2] XIE L,LIU G W,LIU Y N,et al.Prevalence of Helicobacter pylori infection in China from 2014-2023:A systematic review and meta-analysis[J].World J Gastroenterol,2024,30(43):4636-4656.
[3] MALFERTHEINER P,MEGRAUD F,ROKKAS T,et al.Management of Helicobacter pylori infection:The Maastricht VI/Florence consensus report[J].Gut,2022:gutjnl-2022-327745.
[4] IHTESHAM A,MAQBOOL S,NADEEM M,et al.Helicobacter pylori induced Immune Thrombocytopenic Purpura and perspective role of Helicobacter pylorieradication therapy for treating Immune Thrombocytopenic Purpura[J].AIMS Microbiol,2021,7(3):284-303.
[5] SAVIANO A,MORABITO LOPRETE M R,PIGNATARO G,et al.Helicobacter pylori,atherosclerosis,and coronary artery disease:A narrative review[J].Medicina(Kaunas),2025,61(2):346.
[6] NAWACKI Ł,CZYŻ A,BRYK P,et al.Can urea breath test(UBT)replace rapid urea test(RUT)?[J].Pol Przegl Chir,2018,90(5):44-48.
[7] LI Y,CHOI H,LEUNG K,et al.Global prevalence of Helicobacter pylori infection between 1980 and 2022:A systematic review and meta-analysis[J].Lancet Gastroenterol Hepatol,2023,8(6):553-564.
[8] REN S,CAI P,LIU Y,et al.Prevalence of Helicobacter pylori infection in China:A systematic review and meta-analysis[J].J Gastroenterol Hepatol,2022,37(3):464-470.
[9] SAVOLDI A,CARRARA E,GRAHAM D Y,et al.Prevalence of antibiotic resistance in Helicobacter pylori:A systematic review and meta-analysis in world health organization regions[J].Gastroenterology,2018,155(5):1372-1382.e17.
[10] Clinical and Laboratory Standards Institute(CLSI).Performance standards for antimicrobial susceptibility testing.33nd ed[S].Wayne,PA:CLSI,2023.
[11] 黄勋,邓子德,倪语星,等.多重耐药菌医院感染预防与控制中国专家共识[J].中国感染控制杂志,2015,14(1):1-9.
[12] SCHUETZ A N,THEEL E S,COLE N C,et al.Testing for Helicobacter pylori in an era of antimicrobial resistance[J].J Clin Microbiol,2024,62(2):e0073223.
[13] 崔俊华,李懿皞,周佳烨,等.幽门螺杆菌检测方法的发展与比较[J].检验医学,2018,33(1):82-87.
[14] TSHIBANGU-KABAMBA E,YAMAOKA Y.Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications[J]. Nat Rev Gastroenterol Hepatol,2021,18(9):613-629.
[15] 李红,杨天阔,申亚琳,等.幽门螺杆菌药敏检测方法研究进展[J].中华医学杂志,2020,100(30):2393-2396.
[16] 张淑贞,李雪宏,黄海燕,等.深圳地区幽门螺杆菌临床分离菌株的耐药性分析[J].新发传染病电子杂志,2021,6(2):79-83.
[17] 中华医学会消化病学分会幽门螺杆菌学组.2022中国幽门螺杆菌感染治疗指南[J].中华消化杂志,2022,42(11):745-756.
[18] CHEY W D,HOWDEN C W,MOSS S F,et al.ACG clinical guideline:Treatment of Helicobacter pylori infection[J].Am J Gastroenterol,2024,119(9):1730-1753.
[19] 李思荃,蔡祥胜,张伟铮,等.伏诺拉生三联疗法治疗幽门螺杆菌的疗效观察[J].广州医药,2024,55(5):489-493,499.
[20] 姜文,孙海,孙邦英.幽门螺杆菌耐药情况及个性化治疗效果分析[J].临床药物治疗杂志,2023,21(5):22-26.
[21] 张菲菲,王启,李曙光,等.幽门螺杆菌临床耐药性及其变化趋势:北京大学人民医院10年数据分析[J].协和医学杂志,2023,14(5):1017-1022.
[22] 夏宁宁,黄丽静,吴以龙,等.闽浙边界地区人群幽门螺杆菌感染及耐药情况研究[J].临床合理用药杂志,2023,16(27):171-174.
[23] DENG R,LIU L,XIE W,et al.Prevalence of Helicobacter pylori antibiotic resistance in patients enrolled in Guangzhou,China[J].Infect Drug Resist,2023(16):5033-5038.
[24] HUANG X,WU B,CHEN Q,et al.Antibiotic resistance profile of Helicobacter pylori to 14 antibiotics:A multicenter study in Fujian,China[J].PeerJ,2023(11):e15611.
[25] 黄继平,黄艳娟,袁小刚,等.深圳龙岗地区幽门螺杆菌耐药状况分析及耐药对治疗的影响[J].实用医学杂志,2015,31(14):2382-2384.
[26] 吕涛,倪丽,司徒伟基,等.深圳市幽门螺杆菌耐药特点多中心研究[J].临床荟萃,2020,35(8):714-718.
[27] LYU T,CHEUNG K S,NI L,et al.High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line Helicobacter pylori therapy in Southern China:A municipality-wide,multicentre,prospective cohort study[J].J Antimicrob Chemother,2020,75(11):3391-3394.
[28] SONG Z,ZHOU L,XUE Y,et al.A comparative study of 14-day dual therapy(esomeprazole and amoxicillin four times daily)and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication:A randomized trial[J].Helicobacter,2020,25(6):e12762.
[29] GAO W,XU Y,LIU J,et al.A real-world exploratory study on the feasibility of vonoprazan and tetracycline dual therapy for the treatment of Helicobacter pylori infection in special populations with penicillin allergy or failed in previous amoxicillin-containing therapies[J].Helicobacter,2023,28(2):e12947.
[30] LEE K H,PARK S Y,JEONG S J,et al.Can aminoglycosides be used as a new treatment for Helicobacter pylori In vitro activity of recently isolated Helicobacter pylori[J].Infect Chemother,2019,51(1):10-20.
[31] 邹傲,刘振宇,杨莉丽,等.深圳地区幽门螺旋杆菌耐药性检测及状况分析[J].深圳中西医结合杂志,2018,28(6):5-7.
[32] WANG J,XIE X,ZHONG Z,et al.Prevalence of antibiotic resistance of Helicobacter pylori isolates in Shanghai,China[J].Am J Transl Res,2022,14(11):7831-7841.
[33] YUN J W,WANG C,YU Y,et al.High-dose amoxicillin-proton pump inhibitor dual therapy as first-line treatment for Helicobacter pylori infection in Northwest China:A prospective,randomised controlled trial[J].Br J Clin Pharmacol,2023,89(1):232-241.

综合性医院门诊幽门螺杆菌感染及耐药情况研究

Investigation of Helicobacter pylori infection and antibiotic resistance in outpatients at a general hospital

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价

[1]	李思荃, 蔡祥胜, 张伟铮, 胡笑仪, 孙宁, 许研. 伏诺拉生三联疗法治疗幽门螺杆菌的疗效观察[J]. 广州医药, 2024, 55(5): 489-493.
[2]	张春燕, 张赐理. 幽门螺杆菌感染与儿童过敏性紫癜患病及预后的相关性研究[J]. 广州医药, 2018, 49(4): 79-81.
[3]	彭卫斌, 容海鹰, 沙卫红, 聂玉强, 杨元生, 李锐清, 朱雅丽, 张明. 含益生菌四联疗法根除幽门螺杆菌的临床疗效[J]. 广州医药, 2017, 48(1): 38-41.
[4]	陈航远, 谭其平, 蒋宇敏. 含多西环素四联疗法对幽门螺杆菌感染消化性溃疡的疗效研究[J]. 广州医药, 2016, 47(5): 86-87.
[5]	周丽丽, 魏良洲. 幽门螺杆菌感染与反流性食管炎关系的研究[J]. 广州医药, 2016, 47(1): 46-48.
[6]	黄鲁, 沈洁. 幽门螺杆菌感染与年龄及血脂异常的相关性[J]. 广州医药, 2016, 47(1): 75-77.